Affinity of human IgG subclasses to mouse Fc gamma receptors

mAbs

Volumn 9, Issue 5, 2017, Pages 767-773

  Dekkers, Gillian ^a   Bentlage, Arthur E H ^a   Stegmann, Tamara C ^a   Howie, Heather L ^b   Lissenberg Thunnissen, Suzanne ^a   Zimring, James ^b   Rispens, Theo ^a   Vidarsson, Gestur ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Bloodworks Northwest Research Institute   (United States)

Author keywords

Fc receptors; Fc R; IgG subclasses; mouse models; surface plasmon resonance

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; STREPTAVIDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; BIOTINYLATION; CONTROLLED STUDY; DISPERSITY; EXPRESSION VECTOR; GENE SEQUENCE; GENETIC MANIPULATION; GENETIC TRANSFECTION; HUMAN; MOUSE; NONHUMAN; ORTHOLOGY; SENSOR; STREPTOCOCCUS PNEUMONIAE; SURFACE PLASMON RESONANCE; ANIMAL; CHEMISTRY;

ANIMALS; HUMANS; IMMUNOGLOBULIN G; MICE; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 85020295252     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1323159     Document Type: Article

References (49)

1. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015; 15:361-70; PMID:25998715; https://doi.org/10.1038/nrc3930
2. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-33; PMID:18370923; https://doi.org/10.1146/annurev.immunol.26.021607.090232
3. Barahona Afonso AF, João CMP. The production processes and biological effects of intravenous immunoglobulin. Biomolecules 2016; 6:15; PMID:27005671; https://doi.org/10.3390/biom6010015
4. Loisel S, Ohresser M, Pallardy M, Daydé D, Berthou C, Cartron G, Watier H. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62:34-42; PMID:17197192; https://doi.org/10.1016/j.critrevonc.2006.11.010
5. Cheon D-J, Orsulic S. Mouse models of cancer. Annu Rev Pathol 2011; 6:95-119; PMID:20936938; https://doi.org/10.1146/annurev.pathol.3.121806.154244
6. Walsh NC, Kenney LL, Jangalwe S, Aryee K-E, Greiner DL, Brehm MA, Shultz LD. Humanized mouse models of clinical disease. Annu Rev Pathol 2016; 187–215; 12:annurev-pathol-052016-100332; PMID:27959627; https://doi.org/10.1146/annurev-pathol-052016-100332
7. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol 2015; 6:262; PMID:26082779; https://doi.org/10.3389/fimmu.2015.00262
8. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 2007; 104:6200-5; PMID:17400754; https://doi.org/10.1073/pnas.0609174104
9. Roopenian DC, Akilesh S. FcRn:The neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; https://doi.org/10.1038/nri2155
10. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; https://doi.org/10.1182/blood-2012-01-380121
11. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes:From structure to effector functions. Front Immunol 2014; 5:520; PMID:25368619; https://doi.org/10.3389/fimmu.2014.00520
12. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcyRIV:A novel FcR with distinct IgG subclass specificity. Immunity 2005; 23:41-51; PMID:16039578; https://doi.org/10.1016/j.immuni.2005.05.010
13. Zhang Z, Goldschmidt T, Salter H. Possible allelic structure of IgG2a and IgG2c in mice. Mol Immunol 2012; 50:169-71; PMID:22177661; https://doi.org/10.1016/j.molimm.2011.11.006
14. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; https://doi.org/10.1182/blood-2008-09-179754
15. Bindon CI, Hale G, Brüggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168:127-42; PMID:3260935; https://doi.org/10.1084/jem.168.1.127
16. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310:1510-2; PMID:16322460; https://doi.org/10.1126/science.1118948
17. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; https://doi.org/10.4161/mabs.19931
18. Reichert JM. Antibodies to watch in 2017. MAbs 2015; 9:167-81; PMID:27960628; https://doi.org/10.1080/19420862.2016.1269580
19. Reichert JM. Antibodies to watch in 2016. MAbs 2016; 8:197-204; PMID:26651519; https://doi.org/10.1080/19420862.2015.1125583
20. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015; 7:9-14; PMID:25529996; https://doi.org/10.4161/19420862.2015.989042
21. Bruhns P, Jönsson F. Mouse and human FcR effector functions. Immunol Rev 2015; 268:25-51; PMID:26497511; https://doi.org/10.1111/imr.12350
22. Vidarsson G, van de Winkel JG. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis 1998; 11:271-8; PMID:17033391; https://doi.org/10.1097/00001432-199806000-00002
23. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JHW, Bleeker WK, Parren PWHI. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189:3430-8; PMID:22956577; https://doi.org/10.4049/jimmunol.1200356
24. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 1988; 85:4852-6; PMID:3387441; https://doi.org/10.1073/pnas.85.13.4852
25. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012; 109:6181-6; PMID:22474370; https://doi.org/10.1073/pnas.1203954109
26. Hayes JM, Frostell A, Cosgrave EFJ, Struwe WB, Potter O, Davey GP, Karlsson R, Anneren C, Rudd PM. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms:A requirement for stable antibody interactions. J Proteome Res 2014; 13:5471-85; PMID:25345863; https://doi.org/10.1021/pr500414q
27. Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One 2015; 10:e0143520; PMID:26657484; https://doi.org/10.1371/journal.pone.0143520
28. Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. MAbs 2016; 1:1512–24; PMID:27492264; https://doi.org/10.1080/19420862.2016.1218586
29. Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula JT. Cell type-specific and site directed N-glycosylation pattern of Fc RIIIa. J Proteome Res 2011; 10:3031-9; PMID:21561106; https://doi.org/10.1021/pr1012653
30. Schasfoort RBM, Andree KC, van der Velde N, van der Kooi A, Stojanović I, Terstappen LWMM. Interpolation method for accurate affinity ranking of arrayed ligand-analyte interactions. Anal Biochem 2016; 500:21-3; PMID:26878776; https://doi.org/10.1016/j.ab.2016.01.023
31. Baudino L, Nimmerjahn F, Shinohara Y, Furukawa J-I, Petry F, Verbeek JS, Nishimura S-I, Ravetch JV, Izui S. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 2008; 181:4107-12; PMID:18768867; https://doi.org/10.4049/jimmunol.181.6.4107
32. White AL, Chan HTC, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011; 187:1754-63; PMID:21742972; https://doi.org/10.4049/jimmunol.1101135
33. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; https://doi.org/10.1126/science.1129594
34. Gavin AL, Leiter EH, Hogarth PM. Mouse fcgammaRI:Identification and functional characterization of five new alleles. Immunogenetics 2000; 51:206-11; PMID:10752630; https://doi.org/10.1007/s002510050033
35. Gavin AL, Tan PS, Hogarth PM. Gain-of-function mutations in FcgammaRI of NOD mice:Implications for the evolution of the Ig superfamily. EMBO J 1998; 17:3850-7; PMID:9670002; https://doi.org/10.1093/emboj/17.14.3850
36. Maresch D, Altmann F. Isotype-specific glycosylation analysis of mouse IgG by LC-MS. Proteomics 2016; 16:1321-30; PMID:26960168; https://doi.org/10.1002/pmic.201500367
37. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJR, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-3; PMID:24626930; https://doi.org/10.1126/science.1248943
38. Rösner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Br J Haematol 2013; 161:282-6; PMID:23294176; https://doi.org/10.1111/bjh.12209
39. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68:3863-72; PMID:18483271; https://doi.org/10.1158/0008-5472.CAN-07-6297
40. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; PMID:22186895; https://doi.org/10.1038/ncomms1608
41. Saeland E, Vidarsson G, Leusen JHW, Van Garderen E, Nahm MH, Vile-Weekhout H, Walraven V, Stemerding AM, Verbeek JS, Rijkers GT, et al. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol 2003; 170:6158-64; PMID:12794146; https://doi.org/10.4049/jimmunol.170.12.6158
42. Della Valle L, Dohmen SE, Verhagen OJHM, Berkowska MA, Vidarsson G, Ellen van der Schoot C. The majority of human memory B cells recognizing RhD and tetanus resides in IgM+ B cells. J Immunol 2014; 193:1071-9; PMID:24965774; https://doi.org/10.4049/jimmunol.1400706
43. Kruijsen D, Einarsdottir HK, Schijf MA, Coenjaerts FE, van der Schoot EC, Vidarsson G, van Bleek GM. Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice. J Virol 2013; 87:7550-7; PMID:23637394; https://doi.org/10.1128/JVI.00493-13
44. Sun Y, Park MK, Kim J, Diamond B, Solomon A, Nahm MH. Repertoire of human antibodies against the polysaccharide capsule of streptococcus pneumoniae serotype 6B. Infect Immun 1999; 67:1172-9; PMID:10024557
45. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; https://doi.org/10.1126/science.1144603
46. Howie HL, Delaney M, Wang X, Er LS, Vidarsson G, Stegmann TC, Kapp L, Lebedev JN, Wu Y, AuBuchon JP, et al. Serological blind spots for variants of human IgG3 and IgG4 by a commonly used anti-immunoglobulin reagent. Transfusion 2016; 56:2953-62; PMID:27632931; https://doi.org/10.1111/trf.13812
47. Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods 2014; 65:5-10; PMID:23872061; https://doi.org/10.1016/j.ymeth.2013.07.018
48. Dekkers G, Plomp R, Koeleman CAM, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep 2016; 6:36964; PMID:27872474; https://doi.org/10.1038/srep36964
49. de Lau W, Barker N, Low TY, Koo B-K, Li VSW, Teunissen H, Kujala P, Haegebarth A, Peters PJ, van de Wetering M, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011; 476:293-7; PMID:21727895; https://doi.org/10.1038/nature10337